Nykode Therapeutics ASA (NYKD) - Total Liabilities

Latest as of September 2025: Nkr6.45 Million NOK ≈ $678.20K USD

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has total liabilities worth Nkr6.45 Million NOK (≈ $678.20K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Nykode Therapeutics ASA - Total Liabilities Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's total liabilities have evolved over time, based on quarterly financial data. See NYKD current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Nykode Therapeutics ASA Competitors by Total Liabilities

The table below lists competitors of Nykode Therapeutics ASA ranked by their total liabilities.

Company	Country	Total Liabilities
Macpower CNC Machines Limited NSE:MACPOWER	India	Rs979.43 Million
Mobile Infrastructure Corporation NYSE MKT:BEEP	USA	$228.10 Million
Schloss Wachenheim AG F:SWA	Germany	€260.86 Million
Viva Leisure Ltd AU:VVA	Australia	AU$486.81 Million
Union Bankshares Inc NASDAQ:UNB	USA	$1.50 Billion
Noroo Paint KO:090350	Korea	₩293.75 Billion
Kino Polska TV SA WAR:KPL	Poland	zł114.56 Million
Thuan Duc JSC VN:TDP	Vietnam	₫3.36 Trillion

Liability Composition Analysis (2016–2024)

This chart breaks down Nykode Therapeutics ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NYKD company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	170.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	16.37	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.01	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nykode Therapeutics ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual total liabilities of Nykode Therapeutics ASA from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Nkr17.27 Million ≈ $1.82 Million	-53.24%
2023-12-31	Nkr36.93 Million ≈ $3.89 Million	-42.71%
2022-12-31	Nkr64.46 Million ≈ $6.78 Million	-9.85%
2021-12-31	Nkr71.50 Million ≈ $7.52 Million	+39.71%
2020-12-31	Nkr51.18 Million ≈ $5.39 Million	+1.30%
2019-12-31	Nkr50.52 Million ≈ $5.32 Million	+280.83%
2018-12-31	Nkr13.27 Million ≈ $1.40 Million	+21.29%
2017-12-31	Nkr10.94 Million ≈ $1.15 Million	+528.02%
2016-12-31	Nkr1.74 Million ≈ $183.26K	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$108.07 Million

Nkr1.03 Billion NOK

Market Cap Rank

#18987 Global

#166 in Norway

Share Price

Nkr3.15

Change (1 day)

+0.32%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25